{'fraction_non_alphanumeric': 0.030303030303030304, 'fraction_numerical': 0.006493506493506494, 'mean_word_length': 5.560283687943262, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Drug-Device Combinations: Are They Appropriate for the Aging Population?

Hundreds of marketed products combine drugs with delivery devices. Experts estimate that these drug-device combinations (DDCs) generated nearly $24 billion in sales in 2014. DDCs appeal to clinicians and consumers for several reasons. Drugs delivered with a technology-assist may cause fewer side effects, avoid systemic exposure, result in a higher degree of efficacy, or create consistent blood levels. When physicians prescribe a DDC, consultant pharmacists have a unique role: ensuring patients can use the DDC appropriately. Available DDCs require some degree of eye-hand coordination, and older individuals often have difficulty with vision, dexterity, and grip strength. This review primarily discusses three types of DDC: those designed for diabetics, inhalers, and transdermal DDCs, and the characteristics that can challenge older patients.